Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 97

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 97
---
 and clinical personnel from universities and research institutions. Our consultants and advisors may be employed
by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability
to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth.

As of the date hereof, we have
2 full-time employees, one of whom is the Chief Executive Officer and the other who is engaged in general and administrative functions
and who is located in Asia. In addition, we have engaged and may continue to engage independent contracted consultants and advisors to
assist us with our operations. As our development and commercialization plans and strategies develop, we will need to establish and maintain
effective disclosure and financial controls and make changes in our corporate governance practices. We will need to add a significant
number of additional managerial, operational, sales, marketing, financial and other personnel with the appropriate public company experience
and technical knowledge and we may not successfully recruit and maintain such personnel. Future growth will impose significant added responsibilities
on members of management, including:

| ● | identifying, recruiting, integrating, maintaining and motivating 
 additional employees;                                            |

| ● | managing our internal development efforts effectively, including                                                                              
 clinical, the FDA or other comparable regulatory authority review process for our drug and diagnostics technology candidates, while complying 
 with our contractual obligations to contractors and others; and                                                                               |

| ● | improving our operational, financial and management controls, 
 reporting systems and procedures.                             |

As we refine our operational
strategy to streamline operations, we have adjusted our employment model. The company has shifted from a direct employment approach to
outsourcing key functions, including research and development and back-office operations. While this allows for greater focus and flexibility,
it also introduces dependencies on third-party vendors, which may present new risks related to quality control, data security, and operational
continuity that we are actively managing.

Our future financial performance
and our ability to commercialize our drug candidates will depend, in part, on our ability to effectively manage our future growth, and
our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote
a substantial amount of time to managing these growth activities.

We currently rely, and for
the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants